Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK**

By Davies Andrew   Vardeva Kawitha   Loze Jean-Yves   L’’Italien Gilbert J.   Sennfalt Karin   Baardewijk Marc van  

Current Medical Research and Opinion, Vol. 24, Iss. 11, 2008-11 ,pp. : 3275-3285

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland

By Einarson Thomas R.   Pudas Hanna   Zilbershtein Roman   Jensen Rasmus   Vicente Colin   Piwko Charles   Hemels Michiel E. H.  

Journal of Medical Economics, Vol. 16, Iss. 9, 2013-09 ,pp. : 1096-1105

Informa Healthcare

Access to resources Recommend Favorite

Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective

By Nicholl Deborah   Akhras Kasem S.   Diels Joris   Schadrack Jan  

Current Medical Research and Opinion, Vol. 26, Iss. 4, 2010-04 ,pp. : 943-955

Informa Healthcare

Access to resources Recommend Favorite

Prevalence of Pre-Existing Risk Factors for Adverse Events Associated with Atypical Antipsychotics Among Commercially Insured and Medicaid Insured Patients Newly Initiating Atypical Antipsychotics

By  

Current Drug Safety, Vol. 9, Iss. 3, 2014-11 ,pp. : 227-235

Bentham Science Publishers

Access to resources Recommend Favorite

Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder

By Zhu Baojin   Kulkarni Pandurang M   Stensland Michael D.   Ascher-Svanum Haya  

Current Medical Research and Opinion, Vol. 23, Iss. 11, 2007-11 ,pp. : 2805-2814

Informa Healthcare

Access to resources Recommend Favorite